SCHEMBL8225601

SCHEMBL8225601

CCCCCOc1c(C(=O)Nc2nnn[nH]2)oc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 0.43
▸ RAB9A P51151 9/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ TP53 P04637 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ KMT2A Q03164 5/20 0.39
▸ LMNA P02545 4/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ HTT P42858 2/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ CCR6 P51684 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ RXFP1 Q9HBX9 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10371933 0.83 CYSLTR2 (0.38) —
SCHEMBL7121515 0.79 CXCR2 (0.44) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL10372061 0.78 FGFR1 (0.40) NPC1RAB9ASMN1; SMN2TP53LMNA
SCHEMBL10372228 0.76 NPC1 (0.55) NPC1RAB9ASMN1; SMN2TP53ATM
SCHEMBL10374209 0.76 CYSLTR2 (0.36) KDM4EHSD17B10
SCHEMBL10371019 0.76 TSHR (0.54) NPC1RAB9ASMN1; SMN2TP53ATM
SCHEMBL9248201 0.74 KMT2A (0.41) NPC1RAB9ASMN1; SMN2TP53ATM
SCHEMBL10371010 0.74 ALDH1A1 (0.38) SMN1; SMN2TP53KMT2ALMNAKDM4E
SCHEMBL10372173 0.74 NPC1 (0.42) NPC1RAB9AATMKMT2AKDM4E
SCHEMBL10371048 0.74 NPC1 (0.48) NPC1RAB9ASMN1; SMN2ATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6146636-A ADMINISTERING A PATIENT FOR TREATMENT OF A DISEASE STATE, DISORDER, CONDITION OR AFFLICTION ENTAILING AN EXCESSIVE SYNTHESIS OR RELEASE OF SUBSTANCE P, AN EFFECTIVE AMOUNT OF ROSACEAE FAMILY PLANT EXTRACT AS SUBSTANCE P ANTAGONIST SOCIETE L'OREAL S.A. (FR) 2000-11-14 — — US disclosed
Send feedback